Key Highlights

  • The stock rose USD 0.0747, or 15.07%, to USD 0.5704 in regular trading on November 3, 2026.
  • Nasdaq notified the company on October 26, 2026 that its bid price was below USD 1.00, with a compliance deadline of April 26, 2027.
  • Cash and equivalents were USD 116.8 million at June 30, 2026, down from USD 182.5 million at December 31, 2025.
  • Second quarter 2026 net loss was USD 43.1 million, or USD 0.23 per share, versus USD 52.7 million a year earlier.
  • Navacaprant development was discontinued after two Phase 3 studies missed their primary endpoints.

What Moved Neumora Shares Today (up USD 0.0747, 15.07%)

Neumora Therapeutics (NASDAQ:NMRA) rose 15.07% to USD 0.5704 in regular trading on November 3, 2026, up USD 0.0747 from the November 2 close of about USD 0.4957 (calculated).

The most recent company filing identified was a regulatory filing signed on October 30, 2026 disclosing a Nasdaq notice, which is a negative rather than a positive event. No press release or filing dated November 2 or 3, 2026 was identified as a catalyst, so the gain may reflect a rebound from lows or trading interest after the notice. At under USD 1, the shares are a penny stock, and such stocks can swing sharply, trade thinly and face dilution risk.

What Did the Nasdaq Notice Say?

According to the filing, the company received written notice on October 26, 2026 that its stock closed below the USD 1.00 minimum bid required for the Nasdaq Global Select Market under Listing Rule 5450(a)(1). It has 180 calendar days, until April 26, 2027, to regain compliance by closing at or above USD 1.00 for at least ten consecutive Business days.

If it does not, it may apply to move to the Nasdaq Capital Market, subject to meeting other listing standards and paying a fee. The company said it will monitor the bid price and consider options, including a reverse stock split, and gave no assurance of regaining compliance.

What Is Neumora and How Did It Get Here?

Neumora is a clinical-stage biopharmaceutical company focused on brain diseases. On June 15, 2026 it reported that both KOASTAL-2 and KOASTAL-3 Phase 3 studies of navacaprant in major depressive disorder missed their primary endpoint of change in MADRS score at week 6. In KOASTAL-2, the change was -12.2 for navacaprant against -12.0 for placebo (p=0.813). In KOASTAL-3 it was -10.1 against -10.8 (p=0.480).

The company discontinued navacaprant development, announced a workforce reduction of about 35%, and estimated annualized savings of about USD 10 million against one-time costs of about USD 2 million. In August 2026 it named Joshua Pinto as chief executive.

What Do the Latest Results and Pipeline Show?

Second quarter 2026 results, reported August 14, 2026, showed Research and Development expense of USD 29.3 million, down from USD 38.7 million a year earlier. Net loss was USD 43.1 million, compared with USD 52.7 million in the second quarter of 2025.

Cash and equivalents were USD 116.8 million at June 30, 2026. The company said this should fund its operating plan into the third quarter of 2027.

The remaining programs are NMRA-511, a vasopressin 1a receptor antagonist for Alzheimer's disease agitation, NMRA-898, an M4 positive allosteric modulator for schizophrenia, and NMRA-215, an NLRP3 inhibitor for obesity and cardiometabolic disease.

What Should Readers Watch Next?

The third quarter 2026 report should update cash and spending after the restructuring. Pipeline markers include NMRA-511 data in the fourth quarter of 2026, NMRA-898 Phase 1 data in the second half of 2026, and an IND submission for NMRA-215 in the fourth quarter.